Name of Policy: Automatic Stress Ulcer Prophylaxis Discontinuation
Policy Number: 3364-133-102
Department: Pharmacy
Approving Officer: Chief Operating Officer
Responsible Agent: Director of Pharmacy
Scope: University of Toledo Medical Center

Effective Date: 6/1/2016
Initial Effective Date 7/2014

(A) Principle Statement

It is the responsibility of the Registered Pharmacist to review and evaluate the proper indication for all patients receiving PPI or H2RA therapy for stress ulcer prophylaxis (SUP). When proper indication for SUP cannot be established, it will become the Pharmacist’s responsibility to discontinue SUP therapy to prevent any potential harm to the patient from unnecessary therapy.

(B) Procedure

1. When entering orders for PPI/H2RA/sucralfate therapy, an ordering physician must select an HEO indication for use from a given list of indications.

   - Stress Ulcer Prophylaxis
   - Home medication
   - Diseases Of Esophagus (including stricture and stenosis)
   - Duodenal/Gastric/Peptic Ulcer
   - H. pylori infection
   - Abdominal Pain, Epigastric
   - Barretts Esophagus
   - Dyspepsia & Other Spec Disorders Function Stomach
   - Esophageal Reflux (GERD)
   - Active Upper Gastrointestinal Bleeding

2. A pharmacist will evaluate patient profiles for automatic discontinuation of proton pump inhibitors, H2 blockers, or sucralfate with an indication of stress ulcer prophylaxis in patients who do not meet the following criteria for prophylaxis.

CRITERIA FOR USE

Any one of the following indications:
- Coagulopathy (plt <50, INR >1.5)
- Intubation >48h
- Head Injury (GCS <10)
- Burns >35%
- Major Trauma (ISS>16)
- Spinal Cord Injury
- Perioperative hepatic or renal transplant in ICU
- Partial Hepatectomy / Hepatic Failure
Or any 2 of the following indications:
- ICU stay >7 days
- Sepsis
- Steroid use (>250 mg hydrocortisone, >50 mg methylprednisolone, >60 mg prednisone, >10 mg dexamethasone)
- Occult blood lasting more than 6 days

EXCLUSIONS for automatic discontinuation of treatment with PPI/H2RA/sucralfate:
- Use of a PPI/H2RA/sucralfate prior to admission
- Patient with ICU status
- Acute upper GI bleed
- Erosive esophagitis
- H. pylori treatment
- Gastric or duodenal ulcer
- GERD
- Zollinger-Ellison Syndrome
- Orders for Continuous Infusions of PPI’s or H2RA’s
- Anemia/Positive stool blood occult
- The statement “do not autodiscontinue” as a comment on the original order

3. If patient meets criteria for automatic discontinuation of stress ulcer prophylaxis therapy, the evaluating pharmacist will discontinue therapy in HEO and leave a note in the patient’s chart.
- Any questionable PPI/H2RA/sucralfate use will need to be discussed with the primary team before automatic discontinuation by a pharmacist
4. Pharmacists will document changes in the patient’s medical record.

References:
| Policies Superseded by This Policy: |

*It is the responsibility of the reader to verify with the responsible agent that this is the most current version of the policy.*